G. Kojouharoff

1.4k total citations
22 papers, 932 citations indexed

About

G. Kojouharoff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, G. Kojouharoff has authored 22 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in G. Kojouharoff's work include Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (4 papers). G. Kojouharoff is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (4 papers). G. Kojouharoff collaborates with scholars based in Germany, United States and Netherlands. G. Kojouharoff's co-authors include Werner Falk, Wolfgang Hans, Florian Obermeier, Jürgen Schölmerich, Tilo Andus, Volker Heinemann, Stefan Boeck, Oliver G. Ottmann, Arnold Ganser and D. Hoelzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

G. Kojouharoff

21 papers receiving 912 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Kojouharoff Germany	14	326	285	235	224	150	22	932
Toshifumi Ohkusa Japan	23	494 1.5×	501 1.8×	226 1.0×	703 3.1×	222 1.5×	54	1.5k
Uwe Trefzer Germany	19	456 1.4×	338 1.2×	175 0.7×	618 2.8×	67 0.4×	43	1.5k
Alfredo Colantoni Italy	21	468 1.4×	267 0.9×	345 1.5×	458 2.0×	237 1.6×	35	1.2k
Manolis Roulis United States	10	292 0.9×	202 0.7×	215 0.9×	369 1.6×	132 0.9×	13	863
Karina Barbulescu Germany	10	570 1.7×	183 0.6×	171 0.7×	360 1.6×	94 0.6×	12	1.1k
Mark Van Oene Canada	9	297 0.9×	187 0.7×	550 2.3×	292 1.3×	268 1.8×	9	1.3k
Akira Moh United States	13	311 1.0×	248 0.9×	108 0.5×	502 2.2×	84 0.6×	16	1.2k
Hamid Asadzadeh Aghdaei Iran	19	130 0.4×	260 0.9×	170 0.7×	369 1.6×	121 0.8×	73	961
Delphine Bonnet France	17	124 0.4×	241 0.8×	128 0.5×	250 1.1×	183 1.2×	53	1.0k
Thomas E. Hansen‐Hagge Germany	19	532 1.6×	130 0.5×	185 0.8×	544 2.4×	64 0.4×	33	1.3k

Countries citing papers authored by G. Kojouharoff

Since Specialization

Citations

This map shows the geographic impact of G. Kojouharoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Kojouharoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Kojouharoff more than expected).

Fields of papers citing papers by G. Kojouharoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Kojouharoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Kojouharoff. The network helps show where G. Kojouharoff may publish in the future.

Co-authorship network of co-authors of G. Kojouharoff

This figure shows the co-authorship network connecting the top 25 collaborators of G. Kojouharoff. A scholar is included among the top collaborators of G. Kojouharoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Kojouharoff. G. Kojouharoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rummel, Mathias, Christian Lerchenmüller, Manfred Hensel, et al.. (2019). Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 134(Supplement_1). 343–343. 35 indexed citations

Kropff, Martin, Martin Vogel, Guido Bisping, et al.. (2017). Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Annals of Hematology. 96(11). 1857–1866. 14 indexed citations

Krüger, Stephan, Stefan Boeck, Volker Heinemann, et al.. (2015). Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta Oncologica. 54(7). 993–1000. 5 indexed citations

Kropff, Martin, Martin Vogel, Rudolf Schlag, et al.. (2014). Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study. Blood. 124(21). 3470–3470. 5 indexed citations

Boeck, Stefan, Jens T. Siveke, Steffen Ormanns, et al.. (2013). P-ERK, P-AKT and p53 as Tissue Biomarkers in Erlotinib-Treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From Aio-PK0104. Annals of Oncology. 24. iv12–iv12. 1 indexed citations

Boeck, Stefan, Andreas Jung, Rüdiger P. Laubender, et al.. (2012). EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British Journal of Cancer. 108(2). 469–476. 77 indexed citations

Haas, Michael, Stefan Boeck, Ruediger P. Laubender, et al.. (2012). Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC.. Journal of Clinical Oncology. 30(15_suppl). 4023–4023.

Boeck, Stefan, Dirk Waldschmidt, E. Kettner, et al.. (2010). Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology. 28(18_suppl). LBA4011–LBA4011. 14 indexed citations

Boeck, Stefan, Ursula Vehling‐Kaiser, Dirk Waldschmidt, et al.. (2009). Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anti-Cancer Drugs. 21(1). 94–100. 20 indexed citations

10.

Boeck, Stefan, Thomas Hoehler, G. Seipelt, et al.. (2007). Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Annals of Oncology. 19(2). 340–347. 59 indexed citations

11.

Al-Batran, S-E., Stephan Probst, S. Hollerbach, et al.. (2005). Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study. Journal of Clinical Oncology. 23(16_suppl). 4015–4015. 9 indexed citations

12.

Obermeier, Florian, et al.. (1998). Mucosal damage in chronic DSS-colitis mice is mediated by IL-12 and prevented by IL-10. Gastroenterology. 114. A1053–A1053. 2 indexed citations

13.

Kojouharoff, G., et al.. (1997). Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clinical & Experimental Immunology. 107(2). 353–358. 273 indexed citations

14.

Baum, R. P., A. Niesen, A. Hertel, et al.. (1994). Initial clinical results with technetium-99m-labeled ll2 monoclonal antibody fragment in the radioimmunodetection of b-cell lymphomas. Cancer. 73(S3). 896–899. 29 indexed citations

15.

Müller, H, et al.. (1993). Distribution and infection of langerhans cells in the skin of HIV-infected healthy subjects and AIDS patients. Research in Virology. 144(1). 59–67. 18 indexed citations

16.

Geißler, R. G., Oliver G. Ottmann, G. Kojouharoff, et al.. (1992). Influence of Human Recombinant Interferon-Alpha and Interferon-Gamma on Bone Marrow Progenitor Cells of HIV-Positive Individuals. AIDS Research and Human Retroviruses. 8(4). 521–525. 14 indexed citations

17.

Geißler, R. G., Arnold Ganser, Oliver G. Ottmann, et al.. (1991). TIBO R82913, A New HIV-1 Inhibiting Agent, Does Not Inhibit Hematopoietic Progenitor Cells. AIDS Research and Human Retroviruses. 7(12). 1021–1023. 1 indexed citations

18.

Geißler, R. G., Oliver G. Ottmann, M Eder, et al.. (1991). Effect of recombinant human transforming growth factor beta and tumor necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons. Annals of Hematology. 62(5). 151–155. 25 indexed citations

19.

Kojouharoff, G., Oliver G. Ottmann, Hagen von Briesen, et al.. (1991). Infection of granulocyte/monocyte progenitor cells with HIV1. Research in Virology. 142(2-3). 151–157. 17 indexed citations

20.

Hoegen, Ilka von, Werner Falk, G. Kojouharoff, & Peter H. Krammer. (1989). Internalization of interleukin 1 (IL 1) correlates with IL 1‐induced IL 2 receptor expression and IL 2 secretion of EL4 thymoma cells. European Journal of Immunology. 19(2). 329–334. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact